CanSino Biologics (06185.HK): DTCP-Hib-MCV4 combined vaccine initiates Phase I clinical trial and completes enrollment of the first subject.

The Zhitong Finance and Economics APP reported that Kangxinuo Biology (06185.HK) announced that the company's research and development of the adsorbed cell-free quadrivalent (component) white cell pertussis (DTcP) b-type influenza Haemophilus influenzae type b (Hib) - ACYW135 Group Meningococcal (MCV4) conjugate vaccine (DTcP-Hib-MCV4 conjugate vaccine) has officially started Phase I clinical trials recently and has completed the enrollment of the first subject.